Omega Healthcare Investors Signals Confident 2026 Earnings Path
Omega Healthcare Investors ((OHI)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Omega Healthcare Investors’ latest earnings call struck a notably upbeat tone, with management emphasizing accelerating growth, active capital deployment, and a stronger balance sheet. While they called out real risks around Genesis’ bankruptcy, loan repayments, and the new RIDEA strategy, executives argued that robust deal flow and improving coverage metrics leave the REIT well positioned heading into 2026.
Solid Q4 Results Underscore Earnings Momentum
Q4 revenue climbed to $319 million from $279 million a year earlier, while net income jumped to $172 million, or $0.55 per share, from $116 million, or $0.41 per share. Adjusted FFO reached $250 million, or $0.80 per share, and FAD came in at $238 million, or $0.76 per share, edging higher versus the prior quarter.
Full-Year Growth Backed by Aggressive Capital Deployment
For the full year, both AFFO and FAD expanded more than 8% versus 2025, demonstrating steady earnings growth. Omega also deployed about $1.1 billion of capital, directing roughly two-thirds into senior housing and U.K. care homes, with $334 million of new Q4 investments and a further $212 million closing shortly after quarter end.
Strategic Partnerships and New Platforms Take Shape
The REIT deepened its relationship with Sabra by forming a $222 million real estate joint venture and taking a $93 million, 9.9% equity stake in Sabra’s operating company with a minimum 8% cash return. Omega also launched its RIDEA strategy across U.S. senior housing and U.K. care homes and committed up to $64 million to Canadian development projects with optional equity conversion.
Coverage Metrics Signal Improving Credit Quality
Portfolio credit quality continued to firm, with trailing 12‑month EBITDAR coverage for the triple‑net and mortgage core portfolio improving to 1.57x from 1.55x. Management highlighted that this sits above industry averages, reinforcing confidence in tenant health and providing additional cushion behind lease payments.
Deleveraging Drive Bolsters Balance Sheet and Liquidity
Omega reduced funded debt by more than $700 million, including the early payoff of $600 million in senior unsecured notes and other secured borrowings. Year‑end cash stood at $27 million, but the company had over $1.7 billion of capacity on its $2 billion revolver, alongside a new $2 billion at‑the‑market equity program, supporting future deal activity.
Pipeline and 2026 Outlook Underpin Growth Narrative
Management described a diversified 2026 pipeline split roughly one‑third each among skilled nursing, senior housing, and U.K. care homes. With this backlog and recent investments, Omega issued 2026 adjusted FFO guidance of $3.15–$3.25 per share and signaled expectations for continued portfolio expansion and capital deployment.
High-Yield Deals Offer Attractive Return Potential
The company closed a skilled nursing portfolio in Georgia at a 10.6% lease yield and reported current SNF opportunities near 10% yields. Omega is underwriting to unlevered internal rates of return in the low‑ to mid‑teens, pointing to disciplined pricing and the ability to buy assets below replacement cost.
Genesis Bankruptcy Casts a Cloud of Uncertainty
Genesis’ Chapter 11 filing affects 31 Omega‑leased facilities that generate $52 million in annual rent and a $129 million first‑lien term loan. A required second auction has pushed expected resolution into the back half of 2026, leaving timing and recovery uncertain even as management remains confident in the collateral backing its exposure.
Loan Runoff and Asset Sales Pressure Near-Term FAD
Guidance bakes in heavy loan repayment activity, with $157 million of $213 million in 2026‑maturing mortgages and $196 million of $267 million in non‑real‑estate loans assumed to pay down. Asset sales of about $15–$25 million per quarter, plus recent $100 million of dispositions and $61 million of loan repayments, have already trimmed quarterly FAD by roughly $2.1 million.
Cash Constraints and Equity Issuance Raise Dilution Questions
Omega ended the year with modest on‑balance cash, leaning instead on its revolver and equity markets to fund growth. The company issued around 7.8 million common shares and OP units over two quarters, including 5.5 million OP units valued at $222 million in Q4, adding to shareholder dilution even as the new investments are expected to be accretive over time.
RIDEA and SHOP Expansion Increases Operational Volatility
The move into RIDEA and SHOP structures shifts Omega away from its traditional triple‑net model toward more direct operating exposure. Early returns are variable by asset, with yields ranging from high single‑digits upward, increasing complexity and earnings volatility until the platform gains scale and operating track record.
Dividend Policy Nearing a Tax-Driven Inflection Point
Despite some improvement, the dividend payout remains high at 84% of AFFO and 88% of FAD, leaving limited cushion. Management indicated they are nearing a point where a dividend increase could be required for tax purposes once FAD payout falls into the low‑80s, putting additional pressure on sustaining cash flow growth.
Guidance Frames 2026 as a Year of Execution
Omega’s 2026 adjusted FFO guidance of $3.15–$3.25 per share includes closed investments through early February, planned loan repayments, and expected asset sales but excludes undisclosed future deals or capital‑markets moves. Management sees potential upside toward the high end from additional Maplewood cash, shifts in repayment or sale timing, and lower G&A, all building on 2025’s >8% AFFO and FAD growth and $1.1 billion deployed.
Omega Healthcare’s call painted a picture of a REIT leaning into growth while actively cleaning up its balance sheet and credit profile. The opportunities in high‑yield acquisitions and a strong pipeline appear to outweigh the Genesis overhang, loan runoff drag, and higher operating risk, leaving the story attractive but heavily dependent on flawless execution through 2026.
